<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051544</url>
  </required_header>
  <id_info>
    <org_study_id>06201</org_study_id>
    <secondary_id>2008-007016-15</secondary_id>
    <nct_id>NCT01051544</nct_id>
  </id_info>
  <brief_title>Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive</brief_title>
  <acronym>RESIST NAIVE</acronym>
  <official_title>Randomised Study of First TIME Immunotolerance Induction in Patients With Severe Type A Haemophilia With Inhibitor at High Risk of Failure: Comparison of Induction of Immune Tolerance With FVIII Concentrates With or Without Von Willebrand Factor Acronym: RES.I.S.T.- Naive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charta Fondazione</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grifols Biologicals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biotest Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF
      concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune
      tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for
      success.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The presence of Factor VIII (FVIII) inhibitor prevents FVIII infusions from working properly
      and makes treatment of bleeding episodes very difficult. Having an inhibitor is a serious and
      life-threatening complication in patients with Hemophilia. The usual treatment of patients
      with FVIII inhibitors involves &quot;immune tolerance induction&quot; (ITI). Immune Tolerance means
      that the body can accept infused FVIII and that FVIII is again effective in controlling
      bleeds. ITI involves giving high doses of FVIII regularly until the inhibitor disappears.
      This treatment is not always effective. The inhibitor persists in about 1 in 5 patients who
      undergo ITI.

      There are 2 types of FVIII concentrates: FVIII concentrates derived from human plasma, which
      contain the von Willebrand factor, and concentrates of FVIII without VWF (recombinant or
      plasma derived). Both types of concentrates are commonly used to induce immune tolerance in
      patients with Hemophilia A. Retrospective studies in subjects with hemophilia and inhibitors
      at risk for failing ITI, have indicated a higher rate of success if patients were treated
      with von Willebrand containing factor VIII concentrates. It is not known whether the addition
      of Von Willebrand factor offers an advantage to achieving immune tolerance.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 25, 2009</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary end point is the success in inducing immune tolerance, defined as: the abolition of the inhibitor to &lt; 0.6 BU within 33 months of ITI with a factor VIII recovery ≥ 66% and half-life ≥ 6 hrs, and measured after a 72-hour washout period.</measure>
    <time_frame>33 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of relapse, up to 12 months after achievement of Immune Tolerance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve partial or complete success as defined in the protocol.</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Compliance to treatment</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of Care</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Severe Hemophilia A</condition>
  <arm_group>
    <arm_group_label>von Willebrand factor-free FVIII concentrates</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with FVIII concentrates</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FVIII/VWF concentrates</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with FVIII/VWF concentrates</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FVIII Concentrates</intervention_name>
    <description>Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.</description>
    <arm_group_label>von Willebrand factor-free FVIII concentrates</arm_group_label>
    <other_name>Including but not limited to:</other_name>
    <other_name>Advate</other_name>
    <other_name>Beriate P</other_name>
    <other_name>Hemofil M</other_name>
    <other_name>Helixate</other_name>
    <other_name>Kogenate</other_name>
    <other_name>Kogenate SF</other_name>
    <other_name>Monarch M</other_name>
    <other_name>Monoclate</other_name>
    <other_name>Recombinate</other_name>
    <other_name>Refacto</other_name>
    <other_name>Replenate</other_name>
    <other_name>Xyntha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FVIII/VWF concentrates</intervention_name>
    <description>Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.</description>
    <arm_group_label>FVIII/VWF concentrates</arm_group_label>
    <other_name>Including but not limited to:</other_name>
    <other_name>Koate-DVI</other_name>
    <other_name>8Y</other_name>
    <other_name>Optivate</other_name>
    <other_name>Alphanate</other_name>
    <other_name>Fahndi</other_name>
    <other_name>Haemate P</other_name>
    <other_name>Humate P</other_name>
    <other_name>Haemoctine SDH</other_name>
    <other_name>Octanate</other_name>
    <other_name>Wilate</other_name>
    <other_name>Emoclot DI</other_name>
    <other_name>Factane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. severe hemophilia A (FVIII&lt;1%);

          2. male, any age;

          3. high responders (peak inhibitor levels &gt; 5 BU);

          4. any inhibitor level at study enrolment;

          5. ability and willingness to participate in the study;

          6. at least one of the following risk factors for ITI failure:

               -  peak inhibitor titer &gt; 200 BU

               -  titer at ITI start &gt; 10 BU

               -  age &gt; 7 years

               -  time between inhibitor occurrence and ITI &gt; 2 years

          7. absence of high risk of cardiovascular, cerebrovascular or other thromboembolic events
             as deemed by the treating clinician.

        Exclusion Criteria:

          1. concomitant systemic treatment with immunosuppressive drugs;

          2. concomitant experimental treatment;

          3. previous ITI attempt;

          4. previous history of myocardial infarction and/or cerebral stroke.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia P Ewing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Professor of Pediatrics, City of Hope National Medical Center, Dept. of Pediatrics, 1500 E. Duarte Rd. Duarte, CA 91010</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>http://www.itistudy-resist.com/</url>
  </link>
  <link>
    <url>http://www.isth.org</url>
  </link>
  <link>
    <url>http://www.wfh.org</url>
  </link>
  <link>
    <url>http://www.eahad.org</url>
  </link>
  <link>
    <url>http://www.itistudy-resist.com/information.htm</url>
  </link>
  <link>
    <url>http://www.hemophilia.org</url>
  </link>
  <link>
    <url>http://www.aiceonline.it</url>
  </link>
  <link>
    <url>http://hematology.org</url>
  </link>
  <link>
    <url>http://www.aspho.org</url>
  </link>
  <reference>
    <citation>Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia. 1996 Apr;2(2):95-9. doi: 10.1111/j.1365-2516.1996.tb00022.x.</citation>
    <PMID>27214015</PMID>
  </reference>
  <reference>
    <citation>Kreutz W: Immune tolerance induction (ITI) in Haemophilia A-patients with inhibitors - the choice of concentrate affecting success. Haematologica2001; 86 (S4):16-20</citation>
  </reference>
  <reference>
    <citation>Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM; RITS-FITNHES Study Group. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia. 2007 Jul;13(4):373-9.</citation>
    <PMID>17610550</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ITI</keyword>
  <keyword>HAEMOPHILIA A</keyword>
  <keyword>INHIBITORS</keyword>
  <keyword>VWF/FVIII Concentrates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

